MKI67 and neoplasm: The SKLB-D18-treated groups demonstrated a dose-dependent decrease in Ki-67 positive, with less than 20% Ki-67 positive area in the 50 mg/kg SKLB-D18, indicating superior anti-tumor activity compared to the combination therapy of BVD-523 and XMD8-92.